/PRNewswire/ The in-vitro colorectal cancer screening tests market size is anticipated to record a valuation of USD 1.12 billion by 2027, according to the.
Investegate |AstraZeneca PLC Announcements | AstraZeneca PLC: Lynparza approved in China for prostate cancer investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.
Trial PROSPERs China’s fight against advancing prostate cancer
New results from the PROSPER trial helped persuade the Chinese government to approve enzalutamide for adult patients diagnosed with advanced non-metastatic castration-resistant prostate cancer,
Peter Doyle reports
It might be coincidental. But eight months after a joint study by the Peking First University Hospital and National Urological Cancer Center of China in Beijing found a lack of effective therapies in the world’s most populous country for patients with advanced prostate cancer, China’s medicine regulator, the National Medical Products Administration (NMPA), approved the oral androgen-receptor inhibitor enzalutamide for the treatment of adult men with non-metastatic castration-resistant prostate cancer (nmCRPC) with high risk of metastasis.